Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition-Reference-Cited by-同舟云学术

Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition

Published:2022-03 Issue: Volume:438 Page:115905
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Maher Jonathan M.,Zhang Rui,Palanisamy Gopinath,Perkins Kimberly,Liu Lynda,Brassil Patrick,McNamara Alexander,Lo Arthur,Hughes Adam D.,Kanodia Jitendra,Kulyk Svitlana,Nikula Kristen J.,Dengler Hart S.,Scandurra Amy,Lua Ingrid,Harstad Eric

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference36 articles.

1. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals;Alexander;Inhal. Toxicol.,2008

2. Induction of heart valve lesions by small-molecule ALK5 inhibitors;Anderton;Toxicol. Pathol.,2011

3. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor;Bonniaud;Am. J. Respir. Crit. Care Med.,2005

4. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis;Borzone;Am. J. Respir. Crit. Care Med.,2001

5. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice;Carvalho;J. Cell Sci.,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α_vβ₆ Integrin Inhibitors;Journal of Medicinal Chemistry;2024-09-13

2. Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery;Respiratory Research;2024-06-01

3. Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer;Advanced Materials;2023-10-18

4. The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases;Expert Opinion on Drug Discovery;2022-12-26